COMP <GO>
INDP vs CBIO // EV/EBITDA & P/E VALUATION
Indaptus Therapeutics Inc. (NASDAQ) VS. Crescent Biopharma Inc. (NASDAQ) • 15-METRIC TALLY: INDP 2
— CBIO 2
■ METRIC PARITY
LAST: $3.34 (+0.30%) • MKT CAP: $513.0M
valuation
—
LAST: $14.07 (+4.22%) • MKT CAP: $522.6M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (INDP VS. CBIO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | INDP | CBIO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.89% | -13.86% | +10.97 | INDP | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | 1.40% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 6.36 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 3/9 | -1.00 | CBIO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 54.2 | 46.1 | +8.11 | INDP | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $513.0M | $522.6M | -$9.7M | CBIO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | INDP REV | CBIO REV | INDP GROSS % | CBIO GROSS % | INDP FCF | CBIO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $10.8M | — | — | -$14.8M | -$72.5M |
| FY 2024 | $0 | $0 | — | — | -$12.3M | -$31.1M |
| FY 2023 | $0 | $0 | — | — | -$13.4M | -$34.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
INDP // BETA —
CBIO // BETA —